Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EBIT: 2019-2025

Historic EBIT for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -$188.8 million.

  • Avidity Biosciences' EBIT fell 92.40% to -$188.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$612.5 million, marking a year-over-year decrease of 88.63%. This contributed to the annual value of -$378.9 million for FY2024, which is 60.84% down from last year.
  • Avidity Biosciences' EBIT amounted to -$188.8 million in Q3 2025, which was down 10.32% from -$171.1 million recorded in Q2 2025.
  • Avidity Biosciences' EBIT's 5-year high stood at -$23.9 million during Q1 2021, with a 5-year trough of -$188.8 million in Q3 2025.
  • Its 3-year average for EBIT is -$100.5 million, with a median of -$82.6 million in 2024.
  • Data for Avidity Biosciences' EBIT shows a maximum YoY crashed of 287.92% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Avidity Biosciences' EBIT stood at -$38.5 million in 2021, then tumbled by 38.08% to -$53.2 million in 2022, then declined by 25.40% to -$66.7 million in 2023, then tumbled by 81.28% to -$121.0 million in 2024, then plummeted by 92.40% to -$188.8 million in 2025.
  • Its EBIT stands at -$188.8 million for Q3 2025, versus -$171.1 million for Q2 2025 and -$131.5 million for Q1 2025.